SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased factor VIII levels in patients with severe hemophilia A.

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access in children, and low patient acceptance.

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding episodes post-treatment.

A medical center in Indianapolis appears to have perfected a new type of treatment for people with hemophilia.

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with the production of Factor VIII for a prolonged period of time thus obviating the need for repeated infusions.

A 42-year-old man has become the first person in Indiana to undergo gene therapy for hemophilia B. The therapy aims to address the root cause of the disorder by enabling the body to produce the missing clotting factor.

Indian scientists successfully use gene therapy to treat severe haemophilia A, a rare hereditary condition with promising results.